HCB 101
Alternative Names: HCB-101; HLX-701; SIRPα-Fc fusion protein - HanchorBioLatest Information Update: 15 Dec 2025
At a glance
- Originator HanchorBio
- Developer HanchorBio; Shanghai Henlius Biotech
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies; Solid tumours
- Phase I/II Colorectal cancer; Non-small cell lung cancer
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 11 Dec 2025 Efficacy and adverse events data from a phase Ib/IIa trials in Solid tumours released by HanchorBio
- 11 Dec 2025 Efficacy, pharmacokinetic and adverse events data from a phase I trial in Solid tumours released by HanchorBio
- 07 Nov 2025 Efficacy and adverse events data from a phase I and phase Ib/IIa trials in Solid tumours released by HanchorBio